Biopharmaceutical developers are advancing messenger RNA delivery vehicles designed to selectively express tumor-suppressor proteins.
Lipid Nanoparticle Delivery
Enhanced lipid nanoparticle formulations demonstrated improved clearance rates and tissue-specific targeting in early patient cohorts.